Ophthotech $OPHT Licenses Rights to Develop AAV Gene Therapies for Best Disease from Penn uflorida httpow.lyW2yU30optJ5Âpic.twitter.comGLGyhxHGmW

Ophthotech ($OPHT) Licenses Rights to Develop AAV Gene Therapies for Best Disease from @Penn, @uflorida: http://ow.ly/W2yU30optJ5 pic.twitter.com/GLGyhxHGmW

16:25 EDT 14 Apr 2019 | Genetic Engineering News

Ophthotech ($OPHT) Licenses Rights to Develop AAV Gene Therapies for Best Disease from @Penn, @uflorida: http://ow.ly/W2yU30optJ5  pic.twitter.com/GLGyhxHGmW

More From BioPortfolio on "Ophthotech ($OPHT) Licenses Rights to Develop AAV Gene Therapies for Best Disease from @Penn, @uflorida: http://ow.ly/W2yU30optJ5 pic.twitter.com/GLGyhxHGmW"